Low Level Laser Therapy Versus Benzydamin in Prevention and Treatment of Oral Mucositis

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 5, 2021

Primary Completion Date

January 30, 2022

Study Completion Date

February 1, 2022

Conditions
Stomatitis (Oral Mucositis)
Interventions
DRUG

0.15% bezaydamine hydrochloride.

0.15% bezaydamine hydrochloride was applied in oral mucosa in Patients with head and neck cancer under RT, CT treatment.

DEVICE

low power laser with a wavelength of 870 nm

the irradiations will be done three times a week using low power laser with a wavelength of 870 nm. The irradiation mode will be punctual and in contact, perpendicular to the oral mucosa. The power will be 60 mW, energy density of 6 J/cm2. Irradiation time will be 6 seconds per point based on the laser beam spot size of 0.55cm2

Trial Locations (1)

71511

Faculty of dental medicine Al-Azhar University (Assiut branch), Asyut

All Listed Sponsors
lead

Al-Azhar University

OTHER

NCT05034068 - Low Level Laser Therapy Versus Benzydamin in Prevention and Treatment of Oral Mucositis | Biotech Hunter | Biotech Hunter